Indonesia Nears First-Ever Plasma Fractionation Plant — A Breakthrough in Biopharmaceutical Self-Sufficiency

Indonesia is poised to complete its first plasma fractionation facility in Karawang, marking a potential turning point in national healthcare resilience and the domestic supply of critical blood-derived medicines. This development could reshape treatment access for millions and strengthen the nation’s biopharma capabilities.

Indonesia is on the brink of a major healthcare achievement with the near completion of the SK Plasma fractionation plant in Karawang, West Java. It’s set to be the largest facility of its kind in Southeast Asia. This plant, developed through a public-private partnership between Indonesia Investment Authority (INA) and South Korean SK Plasma, is expected to begin commercial operations in 2026 and will produce essential plasma-derived medicinal products (PDMPs) such as human immunoglobulin and albumin.

Historically, Indonesia has relied almost entirely on imported PDMPs, exposing the healthcare system to supply vulnerabilities and price pressures. With an annual capacity of approximately 600,000 liters of plasma, the Karawang facility aims to reduce this dependency and significantly lower the cost of lifesaving treatments for immunodeficiency, autoimmune disorders, shock, and severe burns. Experts expect domestic production could reduce prices by around 8–10% compared to imported alternatives, a major win for patients and clinicians alike.

Beyond production, the project encompasses technology transfer and workforce development, as Indonesian technicians and scientists receive specialised training in advanced plasma-processing methods. This investment in human capital is seen as equally important, positioning Indonesia as a regional leader in the biopharmaceutical sector and boosting local capability for future innovation.

For clinicians, the facility’s emergence promises not only improved access to critical therapies but also a strengthened healthcare ecosystem that supports research, clinical trials, and evidence-based care tailored to local needs. As operations ramp up, Indonesia could transition from an importer to an exporter of PDMPs, forging new avenues for regional collaboration and enhancing overall health security across Southeast Asia.